Clinical Study

S1712- A Randomized Phase II Study Of Ruxolitinib (Nsc-752295) In Combination With Bcr-Abl Tyrosine Kinase Inhibitors In Chronic Myeloid Leukemia (Cml) Patients With Molecular Evidence Of Disease

Posted Date: May 13, 2021

  • Investigator: Emily Curran
  • Specialties: Cancer, Leukemia, Oncology
  • Type of Study: Drug

The purpose of this study is to determine how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. The primary outcome is to compare the rate of molecular response 4.5 (MR4.5) between the different treatment arms after 12 months of combination therapy.


Must Have Diagnosis Of Chronic Phase Chronic Myeloid Leukemia Without Any History Of Progression To Accelerated Or Blast Phase Cml, Must Have Been Receiving Tki Treatment For Cml For At Least 12 Months, Must Be Currently Receiving Treatment With Bosutinib, Adequate Organ Function Per Protocol, Prior Malignancy Is Allowed Providing It Does Not Require Concurrent Therapy


Leukemia, Myeloid Leukemia, Cml

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.